News
-
17-Nov-2011
Novartis and collaborators discover new class of antimalarial compounds with potential to both prevent and treat malaria infectionsThe discovery of a new class of dual-acting antimalarial compounds — the imidazolopiperazines (IZPs) — was published in the journal Science online, at the Science Express website today. The findings report on compounds that target both liver and blood infections, attacking the Plasmodium parasite at both stages in its reproduction cycle.
-
17-Nov-2011
The Novartis Malaria Initiative: lessons from a dramatic decadeIn 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria — without profit — for use by public health systems in developing countries.
-
19-Sep-2011
First Novartis company-wide health and well-being initiativeBe Healthy aims to help Novartis Group Company associates around the world embrace healthy lifestyles by providing opportunities for them to take control of their personal health and help prevent future health issues.
-
01-Sep-2011
Fostering innovation among diverse young talentFuture science and business leaders gathered at Novartis as some of the world’s most talented students met and exchanged ideas at the International BioCamp.
-
22-Apr-2011
The Novartis Malaria Initiative: lessons from a dramatic decadeIn 2001, Novartis AG and the World Health Organization (WHO) unveiled a unique 10-year alliance to provide a breakthrough medicine against malaria – without profit – for use by public health systems in developing countries.
The information in the feature stories on these pages was factually accurate on the date of publication. These feature stories remain on Novartis website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
